With strong three-month performance and significant upside potential, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) secures a spot on our list of the 12 hot penny stocks to invest in right now.
On November 25, 2025, Acrivon Therapeutics, Inc. saw H.C. Wainwright’s Emily Bodnar initiate coverage with a “Buy” rating and a $19 price target. The analyst’s bullish rating reflected the company’s strong outlook driven by robust developments in its pipeline, especially the ACR-368 Phase 2b trial. With the inclusion of a third cohort, enrollment and overall response rate are expected to increase, particularly among patients who are less heavily pretreated. Furthermore, this cohort, which does not require a pretreatment biopsy, along with the use of ultra-low-dose gemcitabine, is expected to broaden access to treatment, thereby improving the company’s market positioning.
Meanwhile, on November 13, Acrivon Therapeutics, Inc. announced its Q3 2025 results, where it reported a net loss of $18.2 million, an improvement compared to $22.4 million a year earlier. The company’s strategic focus on endometrial cancer was evident from its R&D expenses, which fell from $18.9 million a year ago to $13.6 million. Moreover, the company closed the quarter with $134.4 million in cash reserves, which will likely fund operations into Q2 2027. The quarter also marked the continued advancement of the ACR-368 trial for endometrial cancer, while progressing the ACR-2316 Phase 1 trial, which showed early signs of clinical activity and tumor shrinkage.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision medicines using its Generative Phosphoproteomics AP3 platform to design targeted treatments.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
